The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Dechert LLP

CIRCA CENTRE, 2929 ARCH STREET, PHILADELPHIA, PA 19104-2808, USA
Tel:
Work +1 215 994 4000
Fax:
Fax +1 215 994 2222
Email:
Web:
www.dechert.com

George G Gordon

Tel:
Work +1 215 994 2382
Email:
Dechert LLP

Work Department

Antitrust/Competition

Career

George G. Gordon, partner and co-leader of Dechert's life sciences practice, focuses his practice on antitrust litigation, counseling and government investigations. Mr. Gordon's experience includes substantial antitrust class action litigation and general antitrust litigation including a number of significant antitrust actions involving claims of monopolization, unlawful price discrimination, unlawful group boycotts, predatory pricing, and monopoly leveraging.

Member

Antitrust and Litigation Sections, American Bar Association

Education

Brandeis University, B.A., Economics, 1988, cum laude with Honors; University of Pennsylvania Law School, J.D., 1991; The London School of Economics and Political Science, High Commendation, 1987


United States: Antitrust

Civil litigation/class actions

Within: Civil litigation/class actions

Jointly led by George Gordon in Philadelphia and Michael Weiner in New York, Dechert LLP’s team handles a mix of contested antitrust matters, including merger-related litigation, multi-forum class actions and opt-out cases. Weiner and Paul Friedman are acting as lead trial counsel to Monsanto and its Precision Planting business in litigation initiated by the DOJ challenging Deere & Co’s acquisition of Precision Planting. Paul Denis is another key individual in the team. In recent developments, Steven Bizar joined from Buchanan Ingersoll & Rooney, Ethan Litwin arrived from Hughes Hubbard & Reed LLP and counsel Gregory Luib was a notable hire from the FTC. Outgoing practitioners were Gorav Jindal, who went to Akin Gump Strauss Hauer & Feld LLP, and Carolyn Hazard, who went to Endo Pharmaceuticals. Craig Falls made partner. Named lawyers are based in Washington DC except where otherwise indicated.

[back to top]

Merger control

Within: Merger control

In addition to representing merging entities, Dechert LLP acts for third parties in reviews of, and litigation arising from, high-profile, high-dollar, industry-transforming transactions. Paul Friedman and Michael Weiner, who are based in Washington DC and New York respectively, are acting as lead trial counsel to Monsanto and its Precision Planting equipment business in defending against a DOJ lawsuit seeking to challenge Deere & Co’s proposed $190m acquisition of the latter. In another highlight, Washington DC’s Paul Denis and others acted for GE in the DOJ’s challenge of the proposed $3.3bn sale of GE Appliances to AB Electrolux. American Airlines, Ritchie Brothers, CVS Health and Albertsons are among other clients. Weiner and George Gordon (Philadelphia) jointly lead the team, which also includes recently promoted partner Craig Falls (Washington DC). Ethan Litwin joined in New York from Hughes Hubbard & Reed LLP, Steven Bizar joined in Philadelphia from Buchanan Ingersoll & Rooney, and counsel Gregory Luib joined in Washington DC from the Federal Trade Commission (FTC). Carolyn Hazard departed for Endo Pharmaceuticals.

[back to top]

United States: Industry focus

Healthcare: life sciences

Within: Healthcare: life sciences

Antitrust specialist George Gordon and corporate partner David Schulman jointly head the global life sciences practice at Dechert LLP, which excels in the corporate and litigation space, as well as in IP counseling and litigation. Endo Pharmaceutical is a key client of the group; in 2016, Gordon led a team of antitrust litigators in Federal Trade Commission v. Endo Pharmaceuticals Inc, et al, in which he defended Endo Pharmaceuticals in the Federal Trade Commission’s challenge to an agreement by the drug manufacturer not to develop an authorized generic drug. Patent litigator Martin Black secured a victory in the District of Delaware against seven manufacturers of generic drugs for the infringement of an additional patent from its Opana ER tablets, which it has exclusively licensed from Mallinckrodt. Other notable mandates included advising Celgene on its $2.6bn collaboration with Jounce Therapeutics to co-develop and commercialize JTX-2011, a preclinical agent being developed to treat tumors, and assisting Janssen Pharmaceutica with the sale of five anesthesia and pain management injectable products to the UK healthcare unit of Indian conglomerate Piramal Enterprises. Capital markets specialist Kristopher Brown is noted for ‘the strength of his client relationships’, and patent attorney and litigator Andrea Reid’s advice is ‘thoughtful and thorough’. Tony Chan is also highly recommended. All individuals mentioned above are based in Philadelphia, New York and Boston.

[back to top]


Back to index

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to